Phase II
Sanofi said that the phase II/III trial studying venglustat in autosomal dominant polycystic kidney disease was scrapped because it “did not meet futility criteria.”
Amgen reunites with Kyowa Kirin on the development and potential commercialization of KHK4083, an atopic dermatitis drug, which impacts nearly 30 million people worldwide.
The FDA approves Truseltiq for patients with previously-treated locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement.
The FDA gave the green light to Amgen’s Lumakras under accelerated approval as a treatment for patients with KRAS mutation whose disease has worsened over time.
Heading into the U.S. Memorial Day holiday weekend and the official start of summer, it was a moderately busy week for clinical trial news. Take a look.
Bristol Myers Squibb has been busy the last two weeks with a string of approvals, positive clinical trial updates and deals. Here’s a look.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
When the pandemic hit, many companies diverted resources aimed at HIV to COVID-19, which ended up pausing some research efforts.
The company says it plans to file an IND for the candidate, dubbed CFT8919, by the middle of next year.
Companies continue to report promising data for vaccines and therapies against COVID-19. Here’s a look.
PRESS RELEASES